Table 1 Patient characteristics at study entry and outcome according to the stage of the disease at inclusion

From: Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation

Pt no. Sex/age (years) Status/reason for inclusion Time a of CHR Best cytogenetic response (time a ) per protocol Best molecular response (time a ) per protocol Outcome (timea)
Chronic phase       
01 M/12 IFN intol. CCR (3 mo) 3 × 10−4 (27 mo) 3 × 10−4 (27 mo); alive (37 mo)
02 F/15 IFN intol. 3 w FISH 50% (3 mo) ND MUD-Tx (6 mo); died from complications (15 mo)
03 M/12 Hem. resist. IFN PHR Partial (1 mo) ND Blast crisis (2 mo); MUD-T (4 mo); alive (22 mo)
04 M/14 Hem. resist. IFN 3 w CCR (6 mo) <10−6 (32 mo) <1 × 10−6 (32 mo); alive (36 mo)
05 F/16 Hem. resist. IFN 1 mo FISH 27% (7 mo) 5 × 10−2 (22 mo) 1 × 10−1 (27 mo); alive (27 mo)
06 M/2 Hem. resist. IFN 3 w CCR (6 mo) 3 × 10−5 (15 mo) 2 × 10−4 (33 mo); alive (34 mo)
07 F/17.5 Hem. resist. IFN none Failure (2 mo) ND   Blast crisis (2 mo); dead (7 mo)
08 F/8 Hem. resist. IFN 6 w FISH neg (7 mo) 3 × 10−3 (14 mo) MUD-Tx (26 mo); died from complications (27 mo)
09 F/10 Hem. relapse IFN 1 mo Minor (3 mo) 4 × 10−2 (18 mo) 5 × 10−2 (23 mo); alive (23 mo)
10 M/14 Cy. resist. IFN CCR (15 mo) <1 × 10−6 (33 mo) <1 × 10−6 (33 mo); alive (36 mo)
11 M/16 Cy. resist. IFN CCR (4 mo) 1 × 10−3 (4 mo) 1 × 10−3 (13 mo); alive (37 mo)
12b M/16 Hem. relapse after SCT 3 w FISH 1% (2 mo) bUndetect. trans. (3 mo) Stopped imatinib (12 mo); undetect. trans. (21 mo); alive (21 mo)
13 F/13 Hem. relapse after SCT 1 mo FISH neg (15 mo) ND Stopped imatinib (15 mo); hem. relapse (27 mo); alive (48 mo)
14 M/16 Cy. relapse after SCT CCR (1 mo) <1 × 10−4 (2 mo) Cy. relapse (24 mo); alive (28 mo)
15b M/14 Cy. relapse after SCT FISH 10% (2 mo)b Undetect. trans. (10 mo) Stopped imatinib (22 mo); undetect. trans. and alive (30 mo)
16 M/14 Cy. relapse after SCT FISH neg (5 mo) 1 × 10−4 (20 mo) Second MFD-Tx (27 mo); alive (44 mo)
17b F/16 Cy. relapse after SCT FISH 5% (15 mo) b1 × 10−3 (21 mo) Alive (36 mo)
18 M/9 Cy. relapse after SCT FISH neg (3 mo) <1 × 10−4 (3 mo) Alive (26 mo)
19 F/14 Cy. relapse after SCT FISH neg (1 mo) Undetect. trans. (2 mo) Stopped imatinib (3 mo); undetect. trans. and alive (27 mo)
20 F/16 Cy. relapse after SCT CCR (1 mo) < 1 × 10−6 (5 mo) < 1 × 10−6 (31 cmo); alive (32 mo)
21 F/9 Mol. relapse after SCT Undetect. trans. (9 mo) Stopped imatinib (15 mo); undetect. trans. (24 mo); alive (34 mo)
22 F/6 Mol. relapse after SCT Undetect. trans. (1 mo) Stopped imatinib (1.5 mo); undetect. trans.(26 mo); alive (27 mo)
Advanced phase
23 M/3 AP de novo 3 mo CCR (3 mo) 1 × 10−4 (12 mo) 1 × 10−4 (21 mo); alive (27 mo)
24 F/1 AP de novo 1 mo CCR (6 mo) 4 × 10−4 (6 mo) 1 × 10−3 (36 mo); alive (36 mo)
25 M/13 AP de novo None Minor (3 mo) <10−4 (6 mo) MUD-Tx (7 mo); <10−4 (29 mo), alive (29 mo)
26 F/6 AP de novo 2 w FISH 56% (1 mo) 5 × 10−2 (1 mo) MFD-Tx (1 mo); alive (37 mo)
27 M/10 AP/hem resist. IFN 3 w FISH 34% (4 mo) 1 × 10−4 (12 mo) MUD-Tx (12 mois); m. relapse (24 mo); alive (41 mo)
28 M/13 BC/hem resist. IFN PHR ND 6 × 10−3 (10 w) MUD-Tx (9 mo); died from complications (14 mo)
29b M/13 BC post-SCT 2 mo FISH 64% (2 mo) bND Dead (aspergillosis) (3 mo)
30 M/14 BC post-SCT 2 w FISH 79% (2 w) ND Loss of CHR (1 mo); died from disease (5 mo)
  1. AP: accelerated phase; BC: blast crisis; CP: chronic phase; CHR: complete hematologic response; PHR: partial hematologic response; CCR: complete cytogenetic response; w: week; mo: months; ND: not done; MUD-Tx: matched-unrelated stem cell transplantation; MFD-Tx: matched familial stem cell transplantation; undetect. trans: undetectable transcript; neg: negativity; hem. relapse: hematologic relapse; hem.resist.: hematologic resistance; cy. relapse: cytogenetic relapse; cy.resist.: cytogenetic resistance; mol. relapse: molecular relapse
  2. aTime from inclusion.
  3. bPatients who received two to six (median, 2) donor lymphocyte infusion after starting treatment with imatinib mesylate.